Kura Oncology CLO sells 31,487 shares at $12.63

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported that Chief Legal Officer Teresa Brophy Bair sold 31,487 shares of common stock on August 19, 2026 in an open-market transaction at a weighted average price of $12.63 per share, with trade prices ranging from $12.44 to $12.83. These shares had been acquired upon vesting of restricted stock units between January 26, 2024 and January 26, 2026. After this sale, she directly holds 195,444 shares of Kura Oncology common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on May 20, 2026.

Insider Trade Summary 10b5-1

Net Seller: 31,487 shares

Net Sell 1 txn

Insider Bair Teresa Brophy

Role Chief Legal Officer

Sold 31,487 shs ($398K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	31,487	$12.63	$398K

Holdings After Transaction: Common Stock — 195,444 shares (Direct)

Footnotes (2)

1. F1. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026.
2. F2. This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 31,487 shares of Common Stock Weighted average sale price: $12.63 per share Share price range: $12.44 to $12.83 per share +3 more

6 metrics

Shares sold 31,487 shares of Common Stock Open-market sale on August 19, 2026 by Chief Legal Officer Teresa Brophy Bair

Weighted average sale price $12.63 per share Weighted average for trades executed between $12.44 and $12.83

Share price range $12.44 to $12.83 per share Price range of multiple trades on August 19, 2026

Shares held after transaction 195,444 shares of Common Stock Direct holdings of Teresa Brophy Bair following the reported sale

RSU vesting period January 26, 2024 through January 26, 2026 Period during which RSUs vested and produced the shares later sold

Rule 10b5-1 plan adoption date May 20, 2026 Adoption date of the trading plan under which the sale was executed

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average sale price

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"The shares sold were acquired by the Reporting Person upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KURA report for Teresa Brophy Bair?

Kura Oncology reported that Chief Legal Officer Teresa Brophy Bair sold 31,487 shares of common stock on August 19, 2026 in an open-market transaction at a weighted average price of $12.63 per share, with prices ranging from $12.44 to $12.83.

How many KURA shares does Teresa Brophy Bair hold after this Form 4 transaction?

After the reported sale, Chief Legal Officer Teresa Brophy Bair directly holds 195,444 shares of Kura Oncology common stock, as disclosed in the Form 4 filing.

Was the August 19, 2026 KURA insider sale by Teresa Brophy Bair under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Teresa Brophy Bair on May 20, 2026.

What price range applied to Teresa Brophy Bair’s KURA share sale on August 19, 2026?

The transaction was executed in multiple trades at prices ranging from $12.44 to $12.83 per share, with a weighted average sale price of $12.63 reported.

How were the KURA shares sold by Teresa Brophy Bair originally acquired?

The filing explains that the shares sold were acquired upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:31 PM Accepted by SEC EDGAR 08/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bair Teresa Brophy

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S(1)		31,487	D	$12.63(2)	195,444	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units during the period from January 26, 2024 through January 26, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2026.

2. This transaction was executed in multiple trades at prices ranging from $12.44 to $12.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Teresa Bair	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)